SCHEMBL3247530

SCHEMBL3247530

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(NS(=O)(=O)c4cccc(OC)c4)cc3c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 3/20 0.48
MAPK1 P28482 2/20 0.48
ESR1 P03372 1/20 0.48
BRD4 O60885 1/20 0.47
POLB P06746 11/20 0.46
TDP1 Q9NUW8 6/20 0.46
MAPT P10636 8/20 0.46
THRB P10828 2/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 2/20 0.46
GAA P10253 2/20 0.46
TP53 P04637 4/20 0.45
ITK Q08881 1/20 0.44
ALOX15 P16050 1/20 0.44
BACE1 P56817 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250340 0.93 ALDH1A1 (0.55) HSD17B10L3MBTL1ALDH1A1HPGDMAPK1
SCHEMBL3246250 0.91 HIF1A (0.53) HSD17B10ALDH1A1HPGDMAPK1BRD4
SCHEMBL3254038 0.91 BRD4 (0.55) HSD17B10L3MBTL1ALDH1A1HPGDMAPK1
SCHEMBL3255461 0.90 BRD4 (0.52) HSD17B10ALDH1A1HPGDMAPK1BRD4
SCHEMBL3247456 0.89 BRD4 (0.55) HSD17B10ALDH1A1HPGDMAPK1BRD4
SCHEMBL3246426 0.89 MEN1 (0.44) HSD17B10ALDH1A1HPGDMAPK1BRD4
SCHEMBL3250865 0.89 HSD17B10 (0.50) HSD17B10L3MBTL1ALDH1A1HPGDMAPK1
SCHEMBL3245585 0.89 BRD4 (0.50) HSD17B10L3MBTL1ALDH1A1HPGDMAPK1
SCHEMBL3251802 0.88 BRD4 (0.55) HSD17B10ALDH1A1HPGDMAPK1BRD4
SCHEMBL3252939 0.87 BRD4 (0.45) HSD17B10L3MBTL1ALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 HSD17B10 3847/4885L3MBTL1 4622/4885ALDH1A1 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.